Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07337967

Enrollment

120

Registered

2026-01-13

Start date

2026-01-01

Completion date

2027-09-01

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B Chronic Lymphocytic Leukemia

Brief summary

Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

\- Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.

Exclusion criteria

1\) Patients received chemotherapy. 1. Patients with Active bleeding 2. Patients with recent blood transfusion (less than 2 weeks). 3. Patients on haematinics or vitamin B 12 therapy

Design outcomes

Primary

Measure	Time frame	Description
Reticulocyte count	1 year	Absolute peripheral blood reticulocyte count measured in patients with chronic B-cell lymphoproliferative disorders (CLPDs). Unit of Measure: ×10⁹/L
Reticulocyte percentage	1 year	Percentage of reticulocytes among total red blood cells in peripheral blood of patients with CLPDs. Unit of Measure: %
Immature reticulocyte fraction (IRF)	1 year	Proportion of immature reticulocytes in peripheral blood measured in patients with CLPDs. Unit of Measure: %

Outcome results